29 July 2014

The Royal College of General Practitioners, 30 Euston Square, London

The meeting will start promptly at 10:00 and is expected to finish at approximately 17:00

Venue: The Royal College of General Practitioners, 30 Euston Square, London, NW1 2HD

Please note that this agenda is subject to change prior to the meeting.

Final Agenda

  1. Welcome and introduction to format of meeting
  2. Apologies
  3. Any other business
  4. Minutes from the last Committee meeting held on 24 June 2014
  5. Appraisal of dabrafenib for treating unresectable, advanced or metastatic BRAFV600 mutation-positive melanoma
    5.1.        Declarations of interest - Part 1 only (open session)
    5.2.        Introduction by the Chair, Dr Jane Adam - Part 1 only (open session)
    5.3.      Presentation by the Lead team, Dr Brian Shine and Mr Adrian Griffin - Part 1 and Part 2 (open and closed session)
    5.4.        Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)
  6. Appraisal of empagliflozin combination therapy for treating type 2 diabetes
    6.1.        Declarations of interest - Part 1 only (open session)
    6.2.        Introduction by the Chair, Professor Iain Squire - Part 1only (open session)
    6.3.        Presentation by the Lead team, Professor John McMurray and Dr Simon Bond - Part 1 and Part 2 (open and closed session)
    6.4.        Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) - Part 2 only (closed session)

PDF version of agenda (opens in new window)

Date, time and venue of next meeting 

Next Technology Appraisal (Committee A) Meeting: Wednesday 27 August 2014, 10:00am, the Royal College of General Practitioners, 30 Euston Square, London, NW1 2HD

Please note all timings are approximate.

 

Registration period: 01 to 15 July 2014
Registration is closed.